How to Cite
Abstract
Introduction. Colorectal cancer (CRC) is one of the leading causes of death from cancer in the world and is also one of the most common forms of oncological pathology, which is characterized by a continuing steady increase in morbidity, a significant incidence of relapses, and early metastasis. Among the many signaling cascades that determine the features of the biological behavior of a tumor, great importance is attached to the AKT / mTOR signaling pathway. The study aimed to study the expression of AKT / mTOR signaling pathway components in tumors in patients with colorectal cancer, in connection with the clinical and morphological parameters of the disease and the objective response of the tumor to antitumor treatment.
Materials and methods. The study included 26 patients with colorectal cancer aged 43 to 75 years (average age was 54 years). In the clinics of the Research Institute of Oncology of the Tomsk National Research Medical Center, patients received combined treatment, which included neoadjuvant chemotherapy according to the FOLFOX or XELOX scheme by radical surgery. The study material was normal and tumor tissue was obtained after surgical treatment. The mRNA level of the studied parameters was determined by real-time PCR.
Results and discussion. A wave-like change in the expression of AKT, GSK-3β, the 70S 6 kinase, mTOR was found with an increase in the size of the primary tumor. The presence of lymphogenous metastases and the level of regional lymph node involvement (N1–2) were associated with changes in the mRNA level of the 70S 6 kinase, PTEN, GSK-3β, and mTOR. As a result of neoadjuvant chemotherapy, the level of 4EBP1 mRNA increased by 2.6 times compared with that before treatment. At the same time, the low treatment efficacy was associated with an increase in PDK1 expression and a decrease in c-RAF expression.
Conclusion. Molecular features of the development of colorectal cancer associated with changes in the expression of the components of the AKT / mTOR signaling pathway, depending on the locoregional prevalence of the tumor and the effectiveness of antitumor therapy, have been identified, which affects the prognosis of the disease.
References
Kuipers EJ, Grady WM, Lieberman D et al. Colorectal cancer // Nat Rev Dis Primers. 2015;1:15065. doi:10.1038/nrdp.2015.65
Hu S, Yin J, Yan S et al. Chaetocochin J, an epipolythiodioxopiperazine alkaloid, induces apoptosis and autophagy in colorectal cancer via AMPK and PI3K/AKT/mTOR pathways // Bioorg Chem. 2021;109:104693. doi:10.1016/j.bioorg.2021.104693
Злокачественные новообразования в России в 2019 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020.
Dekker E, Tanis PJ, Vleugels JLA et al. Colorectal cancer // Lancet. 2019;394(10207):1467–1480. doi:10.1016/S0140-6736(19)32319-0
Aranda E, Aparicio J, Alonso V et al. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015 // Clin Transl Oncol. 2015;17(12):972–81. doi:10.1007/s12094-015-1434-4
Mauri G, Sartore-Bianchi A, Russo AG et al. Early-onset colorectal cancer in young individuals // Mol Oncol. 2019;13(2):109–131. doi:10.1002/1878-0261.12417
Narayanankutty A. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence // Curr Drug Targets. 2019;20(12):1217–1226. doi:10.2174/1389450120666190618123846
Pandurangan AK. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways // Asian Pac J Cancer Prev. 2013;14(4):2201–5. doi:10.7314/apjcp.2013.14.4.2201
Wang XW, Zhang YJ. Targeting mTOR network in colorectal cancer therapy // World J Gastroenterol. 2014;20(15):4178–88. doi:10.3748/wjg.v20.i15.4178
Wang H, Liu Y, Ding J et al. Targeting mTOR suppressed colon cancer growth through 4EBP1/eIF4E/PUMA pathway // Cancer Gene Ther. 2020;27(6):448–460. doi:10.1038/s41417-019-0117-7
Liang Y, Zhu D, Zhu L et al. Dichloroacetate Overcomes Oxaliplatin Chemoresistance in Colorectal Cancer through the miR-543/PTEN/Akt/mTOR Pathway // J Cancer. 2019;10(24):6037–6047. doi:10.7150/jca.34650
Gao H, Zhong F, Xie J et al. Erratum: PTTG promotes invasion in human breast cancer cell line by upregulating EMMPRIN via FAK/Akt/mTOR signaling // Am J Cancer Res. 2020;10(4):1274–1276 // Erratum for: Am J Cancer Res. 2016;6(2):425–39.
Xue Y, Balci S, Aydin Mericoz C et al. Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated // Cancer. 2020;126(21):4788–4799. doi:10.1002/cncr.33135
Roper J, Richardson MP, Wang WV et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer // PLoS One. 2011;6(9):e25132. doi:10.1371/journal.pone.0025132
Mao HY, Liu SP, Kong GM et al. FBLN3 inhibited the invasion and metastasis of colorectal cancer through the AKT/mTOR pathway // Neoplasma. 2019;66(3):336–342. doi:10.4149/neo_2018_180703N441. Epub 2019 Feb 14. PMID: 30784281
Ran H, Zhu Y, Deng R et al. Stearoyl-CoA desaturase-1 promotes colorectal cancer metastasis in response to glucose by suppressing PTEN // J Exp Clin Cancer Res. 2018;37(1):54. doi:10.1186/s13046-018-0711-9
Liu J, Zhang K, Cheng L et al. Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin // Drug Des Devel Ther. 2020;14:285–296. doi:10.2147/DDDT.S237393
De Roock W, De Vriendt V, Normanno N et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer // Lancet Oncol. 2011;12(6):594–603. doi:10.1016/S1470-2045(10)70209-6. Epub 2010 Dec 14. PMID: 21163703
Martinelli E, Troiani T, D'Aiuto E et al. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells // Int J Cancer. 2013;133(9):2089–101. doi:10.1002/ijc.28236
Micallef I, Baron B. The Mechanistic Roles of ncRNAs in Promoting and Supporting Chemoresistance of Colorectal Cancer // Noncoding RNA. 2021;7(2):24. doi:10.3390/ncrna7020024
Inaba K, Oda K, Ikeda Y et al. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas // Gynecol Oncol. 2015;138(2):323–31. doi:10.1016/j.ygyno.2015.05.031
Hechtman JF, Sadowska J, Huse JT et al. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants // Mol Cancer Res. 2015;13(6):1003–8. doi:10.1158/1541-7786.MCR-15-0062-T
Galbán S, Apfelbaum AA, Espinoza C et al. A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis // Mol Cancer Ther. 2017;16(11):2340–2350. doi:10.1158/1535-7163.MCT-17-0207
Spirina LV, Kondakova IV, Tarasenko NV et al. Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy-- AKT/m-TOR Pathway and Resistance to Cancer Therapy // Zhongguo Fei Ai Za Zhi. 2018;21(1):63–66. doi:10.3779/j.issn.1009-3419.2018.01.09
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021